These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11867199)

  • 1. Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck.
    Katori H; Baba Y; Imagawa Y; Nishimura G; Kagesato Y; Takagi E; Ishii A; Yanoma S; Maekawa R; Yoshioka T; Nagashima Y; Kato Y; Tsukuda M
    Cancer Lett; 2002 Apr; 178(2):151-9. PubMed ID: 11867199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines.
    Iwasaki M; Nishikawa A; Fujimoto T; Akutagawa N; Manase K; Endo T; Yoshida K; Maekawa R; Yoshioka T; Kudo R
    Gynecol Oncol; 2002 Apr; 85(1):103-7. PubMed ID: 11925127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
    Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer.
    Ohta M; Konno H; Tanaka T; Baba M; Kamiya K; Oba K; Kaneko T; Syouji T; Igarashi A; Nakamura S
    Jpn J Cancer Res; 2001 Jun; 92(6):688-95. PubMed ID: 11429059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor.
    Maekawa R; Maki H; Wada T; Yoshida H; Nishida-Nishimoto K; Okamoto H; Matsumoto Y; Tsuzuki H; Yoshioka T
    Clin Exp Metastasis; 2000; 18(1):61-6. PubMed ID: 11206840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.
    Nakabayashi H; Yawata T; Shimizu K
    BMC Cancer; 2010 Jun; 10():339. PubMed ID: 20587068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer.
    Matsushita A; Onda M; Uchida E; Maekawa R; Yoshioka T
    Int J Cancer; 2001 May; 92(3):434-40. PubMed ID: 11291083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
    Maki H; Hojo K; Tanaka H; Sawada TY; Maekawa R; Yoshioka T
    Clin Exp Metastasis; 2002; 19(6):519-26. PubMed ID: 12405289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166.
    Oba K; Konno H; Tanaka T; Baba M; Kamiya K; Ohta M; Kaneko T; Shouji T; Igarashi A; Nakamura S
    Cancer Lett; 2002 Jan; 175(1):45-51. PubMed ID: 11734335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMI-166, a selective matrix metalloproteinase inhibitor, promotes apoptosis in human pancreatic cancer.
    Gao CC; Gong BG; Wu JB; Cheng PG; Xu HY; Song DK; Li F
    Med Oncol; 2015 Jan; 32(1):418. PubMed ID: 25471789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer.
    Fujino H; Kondo K; Ishikura H; Maki H; Kinoshita H; Miyoshi T; Takahashi Y; Sawada N; Takizawa H; Nagao T; Sakiyama S; Monden Y
    Mol Cancer Ther; 2005 Sep; 4(9):1409-16. PubMed ID: 16170033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
    Liu J; Kuo WL; Seiwert TY; Lingen M; Ciaccio MF; Jones RB; Rosner MR; Cohen EE
    Head Neck; 2011 Dec; 33(12):1774-82. PubMed ID: 21438065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops.
    O-Charoenrat P; Rhys-Evans P; Eccles S
    Int J Cancer; 2002 Aug; 100(5):527-33. PubMed ID: 12124801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
    Donnini S; Monti M; Castagnini C; Solito R; Botta M; Schenone S; Giachetti A; Ziche M
    Int J Cancer; 2007 Mar; 120(5):995-1004. PubMed ID: 17131343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.
    Skipper JB; McNally LR; Rosenthal EL; Wang W; Buchsbaum DJ
    ORL J Otorhinolaryngol Relat Spec; 2009; 71(1):1-5. PubMed ID: 18931526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
    McNally LR; Rosenthal EL; Zhang W; Buchsbaum DJ
    Cancer Gene Ther; 2009 Mar; 16(3):246-55. PubMed ID: 18846112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
    Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S
    Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenic inhibition for the treatment of head and neck cancer.
    Gleich LL; Zimmerman N; Wang YO; Gluckman JL
    Anticancer Res; 1998; 18(4A):2607-9. PubMed ID: 9703916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
    Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
    Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma.
    Riedel F; Götte K; Schwalb J; Bergler W; Hörmann K
    Int J Oncol; 2000 Dec; 17(6):1099-105. PubMed ID: 11078794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.